Non-Hodgkin's lymphoma vaccine - XEME Biopharma

Drug Profile

Non-Hodgkin's lymphoma vaccine - XEME Biopharma

Alternative Names: B-cell lymphoma vaccine - XEME Biopharma; Follicular lymphoma vaccine - XEME Biopharma; Oncoquest-L; Oncoquest-L vaccine

Latest Information Update: 31 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator XEME Biopharma
  • Class Cancer vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 31 Mar 2017 XEME Biopharma's Non-Hodgkin's-lymphoma-vaccine is still at phase I development stage in USA (SC) (Xeme Biopharma pipeline, March 2017).
  • 08 Jun 2016 Oncothyreon is now called Cascadian Therapeutics
  • 02 Mar 2016 XEME Biopharma plans a phase II trial for Follicular lymphoma (First-line therapy, Late-stage disease) in USA (NCT02194751)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top